(function(){var loadHandler=window['sl_{66FAC212-8913-4BBD-A749-35204D72856C}'];loadHandler&&loadHandler(8, '<div id="spr0_3f20aa"><div id="spr1_3f20aa" class="kern slide"><img id="img3_3f20aa" src="data/img0.png" width="960px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_3f20aa" class="kern slide"><div id="spr3_3f20aa" style="left:455.188px;top:198.191px;"><img id="img0_3f20aa" src="data/img6.png" width="399" height="247" alt="" style="left:-0.069px;top:0.142px;"/></div><div id="spr4_3f20aa" style="left:502.245px;top:508.569px;"><div style="width:0px;"><span id="txt0_3f20aa" class="relpos" data-width="173.598633" style="left:54.408px;top:4.044px;">JA Sparano et al. N Engl J Med </span><span id="txt1_3f20aa" class="relpos" data-width="71.442383" style="left:54.403px;top:4.044px;">June 3, 2018</span></div></div><div id="spr5_3f20aa" style="left:618.764px;top:125.076px;"><div style="width:0px;"><span id="txt2_3f20aa" data-width="104.976563" style="left:7.2px;top:1.323px;">TAILORx study</span></div></div><div id="spr6_3f20aa" style="left:164.152px;top:14.683px;"><div style="width:0px;"><span id="txt3_3f20aa" data-width="646.187500" style="left:10.416px;top:-0.448px;">Oncotype Dx: Personalised selection of treatment</span></div></div><div id="spr7_3f20aa" style="left:103.14px;top:201.023px;"><img id="img1_3f20aa" src="data/img7.png" width="339" height="242" alt=""/></div><div id="spr8_3f20aa" style="left:562.273px;top:156.92px;"><div style="width:0px;"><span id="txt4_3f20aa" data-width="211.280273" style="left:7.2px;top:1.323px;">Recurrence Score of 11 to 25</span></div></div><div id="spr9_3f20aa" style="left:207.553px;top:156.92px;"><div style="width:0px;"><span id="txt5_3f20aa" data-width="163.353516" style="left:7.2px;top:1.323px;">Recurrence Score &lt; 10</span></div></div><div id="spr10_3f20aa" style="left:229.784px;top:131.094px;"><div style="width:0px;"><span id="txt6_3f20aa" data-width="125.701172" style="left:7.2px;top:1.323px;">NSABP B20 study</span></div></div><div id="spr11_3f20aa" style="left:312.456px;top:70.298px;"><div style="width:0px;"><span id="txt7_3f20aa" data-width="275.203125" style="left:40.237px;top:0.743px;">Breast Cancer: ER+ve, HER2-ve, LN-ve</span></div><div style="width:0px;"><span id="txt8_3f20aa" data-width="337.649414" style="left:8.917px;top:21.693px;">Who does not need cytotoxic chemotherapy ?</span></div></div><div id="spr12_3f20aa" style="left:171.708px;top:511.612px;"><div style="width:0px;"><span id="txt9_3f20aa" data-width="233.467773" style="left:8.412px;top:1px;">Piak et al J Clin Oncol 24:3726-3734 2006</span></div></div><div id="svg0_3f20aa" style="left:522.982px;top:346.449px;"><svg width="340" height="48" viewBox="0 0 340 48"><path fill="#ffffff" d="M0,0 h339.055 v47.588 h-339.055 Z"/></svg></div><div id="spr13_3f20aa" style="left:525.465px;top:360.37px;"><img id="img2_3f20aa" src="data/img8.png" width="307" height="20" alt="" style="left:0.076px;top:-0.127px;"/></div><div id="svg1_3f20aa" style="left:553.863px;top:377.424px;"><svg width="121" height="22" viewBox="0 0 121 22"><path fill="#ffffff" d="M0,0 h120.617 v21.811 h-120.617 Z"/></svg></div><div id="spr14_3f20aa" style="left:553.863px;top:377.424px;"><div style="width:0px;"><span id="txt10_3f20aa" data-width="105.714844" style="left:7.673px;top:2.082px;">overall survival 93.9%</span></div></div><div id="svg2_3f20aa" style="left:705.36px;top:376.403px;"><svg width="124" height="22" viewBox="0 0 124 22"><path fill="#ffffff" d="M0,0 h123.915 v21.811 h-123.915 Z"/></svg></div><div id="spr15_3f20aa" style="left:705.36px;top:376.403px;"><div style="width:0px;"><span id="txt11_3f20aa" data-width="108.427734" style="left:7.947px;top:2.082px;"> overall survival 93.8%</span></div></div><div id="spr16_3f20aa" style="left:179.391px;top:454.564px;"><div style="width:0px;"><span id="txt12_3f20aa" data-width="601.171875" style="left:10.204px;top:1.323px;">No benefit in addition of chemotherapy in a very significant proportion of patients</span></div></div></div></div>');})();